What is William Blair’s Forecast for APLT Q2 Earnings?

Applied Therapeutics, Inc. (NASDAQ:APLT) – Investment analysts at William Blair dropped their Q2 2025 EPS estimates for Applied Therapeutics in a report released on Tuesday, October 22nd. William Blair analyst L. Hanbury-Brown now expects that the company will earn ($0.11) per share for the quarter, down from their prior estimate of ($0.10). William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.48) per share. William Blair also issued estimates for Applied Therapeutics’ Q3 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.36) EPS.

Applied Therapeutics (NASDAQ:APLT) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $10.00 million.

Several other brokerages have also recently issued reports on APLT. Leerink Partners upped their price objective on Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $12.00 price target on shares of Applied Therapeutics in a research note on Wednesday, July 17th. Finally, Citigroup lifted their price objective on shares of Applied Therapeutics from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $12.50.

Applied Therapeutics Trading Down 0.6 %

Shares of Applied Therapeutics stock opened at $8.92 on Thursday. The firm has a market cap of $1.02 billion, a PE ratio of -4.85 and a beta of 2.04. The stock has a 50 day moving average of $7.14 and a 200 day moving average of $5.68. Applied Therapeutics has a 12 month low of $1.79 and a 12 month high of $9.39.

Institutional Trading of Applied Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its stake in shares of Applied Therapeutics by 198.6% during the first quarter. Janus Henderson Group PLC now owns 6,414,642 shares of the company’s stock valued at $43,555,000 after buying an additional 4,266,179 shares during the last quarter. StemPoint Capital LP boosted its holdings in Applied Therapeutics by 122.3% during the 1st quarter. StemPoint Capital LP now owns 2,017,016 shares of the company’s stock valued at $13,716,000 after acquiring an additional 1,109,864 shares during the period. Artal Group S.A. bought a new position in Applied Therapeutics in the 1st quarter valued at $6,865,000. Propel Bio Management LLC increased its stake in Applied Therapeutics by 13.7% in the first quarter. Propel Bio Management LLC now owns 6,111,906 shares of the company’s stock worth $41,561,000 after purchasing an additional 736,924 shares during the period. Finally, Peregrine Capital Management LLC bought a new stake in shares of Applied Therapeutics during the second quarter worth $3,414,000. Institutional investors own 98.31% of the company’s stock.

Insider Activity at Applied Therapeutics

In other Applied Therapeutics news, CEO Shoshana Shendelman sold 119,591 shares of Applied Therapeutics stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $5.93, for a total transaction of $709,174.63. Following the completion of the transaction, the chief executive officer now directly owns 4,690,839 shares of the company’s stock, valued at $27,816,675.27. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.60% of the stock is currently owned by insiders.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.